Fed Circ to rehear $235m ‘skinny label’ case
The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.
Federal Circuit denies further term extensions to shoulder surgery patentee
The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office.
J&J reaches $6m settlement over counterfeit surgical tools
Johnson & Johnson has settled its case against Advanced Inventory Management, trading as eSutures, which it accused of distributing counterfeit and contaminated surgical tools.
Pfizer to collaborate with Imcyse on new immunotherapy programme
Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Boehringer hits China’s Qilu with cancer drug patent suit
Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.
Coherus secures toripalimab rights for US and Canada
Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada.
Russian drugmakers bypass Gilead to unveil COVID-19 generic
Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Illumina wins PTAB appeal over Columbia DNA patents
Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid.
LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission
The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
